C3 glomerulonephritis

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

6 events
Apr 2025A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases

Suzhou Sanegene Bio Inc. — PHASE2

TrialNOT YET RECRUITING
Mar 2024Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

Omeros Corporation — PHASE2

TrialRECRUITING
May 2023An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Apellis Pharmaceuticals, Inc. — PHASE3

TrialACTIVE NOT RECRUITING
Sep 2021Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

Apellis Pharmaceuticals, Inc. — PHASE2

TrialACTIVE NOT RECRUITING
Oct 2020Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy

Region Skane — PHASE2

TrialRECRUITING
Oct 2019Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

Novartis Pharmaceuticals — PHASE3

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for C3 glomerulonephritis.
Check the disease page for updates →

Clinical Trial Landscape

5 active trials
2Phase 3
3Phase 2
5Total recruiting
Search clinical trials for C3 glomerulonephritis

Recent News & Research

No recent news articles indexed yet for C3 glomerulonephritis.
Search PubMed for C3 glomerulonephritis

Browse all C3 glomerulonephritis news →

Specialist Network

Top 6 by expertise

View all C3 glomerulonephritis specialists →

Quick Actions